| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers G > Headlines for GlaxoSmithKline plc > News item |
GlaxoSmithKline says MAGE-A3 reduces relative cancer risk by 33%
By Lisa Kerner
Charlotte, N.C., June 6 - GlaxoSmithKline said patients treated with its investigational MAGE-A3 Antigen Specific Cancer Immunotherapeutic (ASCI) in non-small cell lung cancer (NSCLC) experienced a one-third reduction in relative risk of cancer recurrence following surgery, compared to a placebo.
All the subjects in the proof-of-concept, randomized, double-blind phase 2 clinical trial had tumors expressing a tumor-specific antigen known as MAGE-A3, which is present in about 35% to 50% of early NSCLC, the most common form of lung cancer.
While not statistically significant, the 33% reduction in relative risk of cancer recurrence warrants continued investigation, according to a company news release.
The results from an interim analysis were presented at the 2006 American Society of Clinical Oncology annual meeting in Atlanta.
Two of the182 patients were withdrawn from the trial due to adverse events. The most commonly reported adverse events were mild local or systemic reactions.
GlaxoSmithKline said the pre-planned interim analysis was performed at a median follow-up of 21 months, at which point 30.3% of patients receiving MAGE-A3 ASCI had relapsed, compared to 41.7% of patients receiving a placebo.
"These first results obtained with our MAGE-A3 ASCI reinforce our belief in the potential application of the ASCI approach in the treatment of cancer," GlaxoSmithKline Biologicals president Jean Stephenne said in the release.
Final results are expected to be available later this year, with phase 3 trials slated to begin in early 2007.
GlaxoSmithKline is a research-based pharmaceutical and health care company based in Philadelphia.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.